SCHEMBL188094

SCHEMBL188094

COc1c(C=O)cccc1B(O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
ERN1 O75460 5/20 0.50
TLR2 O60603 1/20 0.50
TLR1 Q15399 1/20 0.50
TLR6 Q9Y2C9 1/20 0.50
SRC P12931 1/20 0.50
ENPP2 Q13822 1/20 0.44
NFE2L2 Q16236 2/20 0.41
MCL1 Q07820 1/20 0.41
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2787203 0.83 CA1 (0.73) CA1CA2ERN1TLR2TLR1
SCHEMBL1293652 0.80 CA1 (0.42) CA1CA2ERN1TLR2TLR1
SCHEMBL1293651 0.80 CA1 (0.42) CA1CA2ERN1TLR2TLR1
SCHEMBL1597634 0.80 CA1 (0.63) CA1CA2ERN1TLR2TLR1
SCHEMBL3421185 0.78 CA1 (0.72) CA1CA2ERN1TLR2TLR1
SCHEMBL470709 0.78 CA1 (1.00) CA1CA2ERN1TLR2TLR1
SCHEMBL30385316 0.77 CA1 (0.59) CA1CA2ERN1TLR2TLR1
SCHEMBL23108166 0.76 CA1 (0.63) CA1CA2ERN1TLR2TLR1
O-Veratraldehyde SCHEMBL29923149 0.76 SRC (0.67) CA1CA2ERN1TLR2TLR1
O-Veratraldehyde SCHEMBL28289918 0.76 SRC (0.67) CA1CA2ERN1TLR2TLR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4588927-A2 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES Universal Display Corporation (US) 2025-07-23 EP disclosed
US-20240423085-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-12-19 US disclosed
CN-119019459-A Organic electroluminescent material and device 环球展览公司 2024-11-26 CN disclosed
CN-117263992-B Organic metal compound and organic electroluminescent device comprising same 吉林奥来德光电材料股份有限公司 2024-03-26 CN disclosed
US-20240090311-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-03-14 US disclosed
CN-117263992-A Organic metal compound and organic electroluminescent device comprising same 吉林奥来德光电材料股份有限公司 2023-12-22 CN disclosed
CN-116903664-A Organic electroluminescent material and device 环球展览公司 2023-10-20 CN disclosed
WO-2022114117-A1 PALLADIUM COMPLEX, COUPLING REACTION CATAYLST, AND METHOD FOR PRODUCING AROMATIC COMPOUND エヌ・イーケムキャット株式会社 2022-06-02 WO disclosed
WO-2021050688-A1 COMPOUNDS AND USES THEREOF X-CHEM, INC. (US) 2021-03-18 WO disclosed
WO-2021050688-A1 COMPOUNDS AND USES THEREOF X-CHEM, INC. (US) 2021-03-18 WO disclosed
WO-2009144494-A1 PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES ASTRAZENECA AB (SE) 2009-12-03 WO disclosed
EP-2125716-A2 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE Othera Holding, Inc. (US) 2009-12-02 EP disclosed
EP-2120942-A2 DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE Othera Holding, Inc. (US) 2009-11-25 EP disclosed
US-20090048239-A1 Therapeutic compounds MSD ITALIA S.R.L. (IT) 2009-02-19 US disclosed
WO-2009010785-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-01-22 WO disclosed
WO-2009010783-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-01-22 WO disclosed
US-20080280890-A1 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE COLBY PHARMACEUTICAL COMPANY 2008-11-13 US disclosed
WO-2008103613-A2 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE OTHERA HOLDING, INC. (US) 2008-08-28 WO disclosed
US-20080200405-A1 Drug Resistance Reversal In Neoplastic Disease COLBY PHARMACEUTICAL COMPANY 2008-08-21 US disclosed
WO-2008101195-A2 DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE OTHERA HOLDING, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048239-A1 Therapeutic compounds RRP1B, RCE1, CTSZ CA1 4330/4885CA2 4645/4885ERN1 1110/4885
US-20240423085-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD1, OCIAD2, OPRM1 CA1 2710/4885CA2 2808/4885ERN1 2141/4885
US-20080280890-A1 HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE HDGF, HMOX1, HMOX2 CA1 4471/4885CA2 4371/4885ERN1 2840/4885
US-20240090311-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, OXER1, OXSR1 CA1 2392/4885CA2 2315/4885ERN1 971/4885
US-20080200405-A1 Drug Resistance Reversal In Neoplastic Disease VHL, ABCC1, SLC11A2 CA1 1921/4885CA2 1986/4885ERN1 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.